Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now an established option in the clinician’s armamentarium for type 2 diabetes mellitus (T2DM), with a role at almost any stage of therapy. These agents have the potential to improve glucose control without weight gain and with a low risk of hypoglycemia. Importantly, GLP-1 RAs are in a class of incretin mimetics that have shown a positive impact on cardiovascular outcomes. This activity reviews how GLP-1 RAs work and provides guidelines for clinical implementation. An illustrative case study demonstrates real-world practical applications.
eNewsletter with interactive benchmarking
To educate nurse practitioners and physician assistants on the role of GLP-1 RAs in managing T2DM.
After completing this activity, participants should be better able to:
- Describe the risks and benefits of available GLP-1 RAs and their place in clinical practice
- Identify differences between short- and long-acting GLP-1 RAs in order to formulate individualized treatment plans for patients
- Formulate strategies to implement evidence-based guideline recommendations regarding the use of GLP-1 RAs in clinical practice
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
This program has been reviewed and is approved for a maximum of 1.0 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of June 28, 2018. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, the AAPA, or Lilly USA, LLC.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are expected to disclose to the audience any significant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Joy: advisory board: Intarcia, Lilly.
Ms Kruger: advisory board: Intarcia, Sanofi Aventis; advisory board/grant/research support/speakers bureau: Abbott, Lilly, Novo Nordisk; advisory board/grant/research support/speakers bureau/stock: Dexcom; advisory board/speakers bureau: Janssen; grant/research support: Lexicon; grant/research support/speakers bureau: AstraZeneca; speakers bureau: Boehringer Ingelheim, Valeritas.
The Planning Committee for this activity included Ruth Cohen and Warren Beckman of Continuing Education Alliance; and Mark Christiansen, PhD, PA-C, of the University of the Pacific. The members of the Planning Committee have no significant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the eNewsletter in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: June 28, 2018
Expiration date: June 28, 2019
© 2018 Practicing Clinicians Exchange. All Rights Reserved. LPCE93718